Logo

PRLD

Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated • NASDAQ
$1.68 ▲ 0.60% (+0.01)
Market Cap $92.71 M
52w High $4.22
52w Low $0.61
Dividend Yield 0%
P/E -1.14
Volume 232.48K
Outstanding Shares 76.09M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $6.5M ▲ $26.493M ▼ $-19.725M ▲ -303.462% ▼ $-0.26 ▲ $-19.3M ▲
Q2-2025 $0 $32.194M ▼ $-31.231M ▲ 0% $-0.41 ▲ $-31.761M ▲
Q1-2025 $0 ▼ $34.606M ▼ $-32.085M ▼ 0% ▲ $-0.42 ▼ $-34.171M ▼
Q4-2024 $4M ▲ $37.831M ▲ $-28.731M ▲ -718.275% ▲ $-0.38 ▲ $-33.342M ▲
Q3-2024 $3M $37.376M $-32.271M -1.076K% $-0.43 $-33.971M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $54.957M ▼ $94.755M ▼ $36.221M ▼ $58.534M ▼
Q2-2025 $73.216M ▼ $114.918M ▼ $39.08M ▲ $75.838M ▼
Q1-2025 $99.074M ▼ $141.26M ▼ $38.082M ▼ $103.178M ▼
Q4-2024 $133.614M ▼ $175.515M ▼ $44.056M ▲ $131.459M ▼
Q3-2024 $153.626M $197.22M $40.789M $156.431M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-19.725M ▲ $-19.115M ▲ $40.091M ▲ $-5K ▼ $21.78M ▲ $-19.115M ▲
Q2-2025 $-31.231M ▲ $-26.075M ▲ $11.521M ▼ $37K ▲ $-14.517M ▼ $-26.095M ▲
Q1-2025 $-32.085M ▼ $-34.231M ▼ $62.186M ▲ $-160K ▼ $27.795M ▲ $-34.278M ▼
Q4-2024 $-28.731M ▲ $-20.744M ▲ $22.118M ▲ $-34K ▲ $1.34M ▲ $-20.797M ▲
Q3-2024 $-32.271M $-27.296M $10.733M $-131K $-16.694M $-27.359M

Five-Year Company Overview

Income Statement

Income Statement Prelude is still a classic early-stage biotech story: essentially no commercial revenue and a steady pattern of research-driven losses. The loss level has been relatively consistent over the past few years, which suggests management is controlling spending rather than aggressively ramping it. Earnings per share remain negative, but the trend hints at some gradual improvement as the company narrows its focus. Overall, the income statement reflects a company investing heavily in science without yet having any product sales to offset those costs.

Balance Sheet

Balance Sheet The balance sheet shows a company that is slowly drawing down its resources over time. Cash and total assets have trended down since the first years after the IPO, while shareholder equity has also been shrinking as losses accumulate. Debt has appeared but remains modest relative to the size of the company, so the balance sheet is not highly leveraged. The key message is that Prelude still has a positive capital base, but it is much leaner than in its early post-IPO period and increasingly dependent on careful cash management and external funding agreements.

Cash Flow

Cash Flow Cash flows are what you would expect from a young drug developer: money consistently going out to fund research and operations, with nothing yet coming in from product sales. Operating cash burn has been steady rather than exploding, suggesting reasonably disciplined spending. Free cash flow closely tracks operating cash flow, since the company spends very little on physical assets and infrastructure. This profile underlines ongoing reliance on capital raises and partnerships to sustain the pipeline until any future approvals or licensing income.

Competitive Edge

Competitive Edge Prelude operates in a crowded and fast-moving oncology space but is trying to differentiate itself through precision targeting and novel drug modalities. Its emphasis on protein degraders and mutant-selective inhibitors gives it a more specialized profile than many generalist oncology players. The option deal with Incyte is an important form of external validation and adds a stronger partner in an area where Incyte has deep experience. That said, the company remains small, pre-commercial, and exposed to competition from much larger pharma and biotech firms working on overlapping cancer pathways and technologies.

Innovation and R&D

Innovation and R&D Innovation is the core of Prelude’s story. The company is pushing forward in targeted protein degradation, selective kinase inhibition, and an emerging degrader–antibody conjugate platform, all aimed at highly specific cancer drivers. Its focus on first-in-class or best-in-class programs, such as KAT6A degraders and mutant-selective JAK2 inhibition, shows a strategy of going after biologically validated but technically challenging targets. Recent portfolio pruning and program prioritization indicate management is concentrating resources on the most promising assets while still nurturing a broader discovery engine. Overall, the R&D profile is ambitious, science-driven, and high risk, with most value still in preclinical or very early clinical stages.

Summary

Prelude Therapeutics is a pre-revenue oncology biotech with a focused but early-stage pipeline and a financial profile typical of a development-stage company. The income statement and cash flows reflect ongoing investment in research with no commercial offset, while the balance sheet shows a shrinking but still positive capital base and modest leverage. Competitively, the company leans on its depth in protein degradation and mutant-selective inhibition, plus a notable partnership with Incyte, to stand out in a crowded field. The main strengths are scientific specialization and strategic focus; the main risks are clinical uncertainty, dependence on external funding, and concentration in a small number of unproven assets. Outcomes will hinge on clinical data over the next several years and the company’s ability to convert its technology platforms into validated, partnering-ready or ultimately commercial products.

NEWS

November 26, 2025 · 11:10 AM UTC

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Read more

November 20, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD

Read more

November 19, 2025 · 10:40 AM UTC

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Read more

November 12, 2025 · 7:01 AM UTC

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 11, 2025 · 11:24 PM UTC

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

Read more